Synthego Raises $100M in Series D Funding
Summary
The company, which also recently appointed biopharma and technology industry veterans Robert (Bob) Deans, Ph.D., as Chief Scientific Officer, and John Tan, M.B.A., as Chief Operating Officer, will use the proceeds from the financing to expand the capabilities of its proprietary platforms. Led by Paul Dabrowski, CEO and Co-Founder, Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation and gene editing to build platforms for science at scale. has developed platforms designed to produce standardized CRISPR reagents and engineered cells to enable more rapid and precise discovery, validation and genetic pathway analysis that scientists use to conduct basic research, target identification and clinical trials. Robert Deans, Ph.D., brings more than 25 years of experience developing stem cell and gene therapies, as well as translational science and global regulatory expertise to Synthego, where he will serve as Chief Scientific Officer.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
